Natural Product (NP) Details
| General Information of the NP (ID: NP3744) | |||||
|---|---|---|---|---|---|
| Name |
Alpha tricalcium phosphate
|
||||
| Synonyms |
Calcium phosphate; 7758-87-4; TRICALCIUM PHOSPHATE; Synthos; Calcium phosphate tribasic; Calcium orthophosphate; Tricalcium diphosphate; Calcigenol simple; beta-TCP; Phosphoric acid, calcium salt (2:3); Tricalcium orthophosphate; beta-Tricalcium phosphate; Calcium tertiary phosphate; Tertiary calcium phosphate; tri-calcium phosphate; FEMA No. 3081; Calciresorb;TCP; 10103-46-5; Phosphoric acid, calcium salt; UNII-K4C08XP666; tricalcium;diphosphate; tricalcium bis(phosphate); CHEBI:9679; K4C08XP666; Synthograft; Bonarka; Cerasorb; OSferion; Natural whitlockite; Calcium phosphate, 96%, pure; Caswell No. 148; Ceredex; Multifos; Ostram; Vitoss; TricOs; Calipharm T; Tricafos P; Calcium phosphate (3:2); Tricalcium bis(orthophosphate); CCRIS 3668; HSDB 879; JAX TCP; Calcium phosphate (Ca3(PO4)2); Calcium phosphate, for analysis, 35-40% (Ca); Calcium orthophosphate, tri-(tert); Tricalcium phosphate (Ca3(PO4)2); EINECS 231-840-8; EPA Pesticide Chemical Code 076401; Posture (calcium supplement); bone phosphate; Phosphoric acid calcium(2+) salt (2:3); Ca3(PO4)2; Bone ash; calcium-phosphate; alpha-TCP; Calcium phosphates; tricalciumphosphate; EINECS 233-283-6; Posture (TN); Hydroxyapatite Powder; MFCD00015984; Phosphoric acid, calcium salt (1:?); calcium phosphate basic; beta tricalcium phosphate; AI3-25607; alpha-Tricalcium phosphate; Ca3O8P2; EC 231-840-8; BONE POWDER, PURIFIED; INS NO.341(III); INS-341(III); CHEMBL2106566; DTXSID1049803; E-341(III); AKOS015833108; DB11348; S338; Tricalcium bis(orthophosphate), with a fluorine content of less than 0,005 % by weight on the dry anhydrous product; Calcium phosphate, tribasic (ca.37% Ca); CS-0013475; FT-0645103; C08136; D00938; Q278387; UNII-97Z1WI3NDX component QORWJWZARLRLPR-UHFFFAOYSA-H; UNII-279O8I0433 component QORWJWZARLRLPR-UHFFFAOYSA-H; Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, >=95% beta-phase basis (unsintered powder); Calcium phosphate, purum p.a., >=96.0% (calc. as Ca3(PO4)2, KT); Tricalcium phosphate hydrate, nanopowder, <200 nm particle size (BET); alpha-tri-Calcium phosphate, puriss. p.a., >=75% alpha-phase basis (sinterted powder); alpha-tri-Calcium phosphate, Reagent for transient & stable DNA transfections; beta-tri-Calcium phosphate, puriss. p.a., >=95% beta-phase basis (sintered powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (sintered Powder); beta-tri-Calcium phosphate, puriss. p.a., >=98% beta-phase basis (unsintered powder); 21063-37-6
Click to Show/Hide
|
||||
| Disease | Femur fracture [ICD-11: NC72] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
Ca3O8P2
|
||||
| PubChem CID | |||||
| Canonical SMILES |
[O-]P(=O)([O-])[O-].[O-]P(=O)([O-])[O-].[Ca+2].[Ca+2].[Ca+2]
|
||||
| InChI |
1S/3Ca.2H3O4P/c;;;2*1-5(2,3)4/h;;;2*(H3,1,2,3,4)/q3*+2;;/p-6
|
||||
| InChIKey |
QORWJWZARLRLPR-UHFFFAOYSA-H
|
||||
| CAS Number |
CAS 7758-87-4
|
||||
| ChEBI ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Simvastatin | Hyper-lipoproteinaemia | Click to Show/Hide the Molecular Data of This Drug | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vivo Model | Bilateral 5-mm-diameter calvarial defects were created in adult Wistar rats and filled with preparations of different doses of simvastatin (0, 0.01, 0.1, 0.25 and 0.5 mg) combined with a-TCP particles or left empty. | |||||
| Experimental
Result(s) |
When combined with alpha-TCP particles, 0.1 mg simvastatin is the optimal dose for stimulation of the maximum bone regeneration in rat calvarial defects without inducing inflammation. | |||||
